We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bifunctional Dimer Drugs Prove Effective in Parkinson's Disease Yeast Model

By LabMedica International staff writers
Posted on 11 Oct 2016
Print article
Image: Positive alpha-synuclein staining of a Lewy body from a patient with Parkinson\'s disease (Photo courtesy of Wikimedia Commons).
Image: Positive alpha-synuclein staining of a Lewy body from a patient with Parkinson\'s disease (Photo courtesy of Wikimedia Commons).
A team of Canadian neurodegenerative disease researchers used a yeast model system to identify novel drug compounds that were able to block the misfolding of alpha- synuclein (AS) protein, which characterizes the neurons of patients with Parkinson's disease.

The misfolding of alpha-synuclein is a critical event in the death of dopaminergic neurons and the progression of Parkinson’s disease. Investigators at the University of Saskatchewan (Saskatoon, Canada) based their search for new drug candidates on previous studies showing that caffeine had a protective effect against Parkinson’s disease.

The investigators synthesized 30 different “bifunctional dimer” drugs that were attached to a caffeine scaffold structure. In addition to the caffeine scaffold, the drug compounds were augmented by the addition of reagents with known effects, such as nicotine, the diabetes drug metformin, and aminoindan, a research chemical similar to the Parkinson’s drug rasagiline.

The ability of the dimers to interact with alpha-synuclein in a cell system was assayed in a yeast Parkinson's disease model, which expressed an AS-GFP (alpha-synuclein-Green Fluorescent Protein) construct under the control of a galactose promoter.

Results published in the September 27, 2016, online edition of the journal ACS Chemical Neuroscience revealed that while the yeast strain could not grow in the presence of five millimolar galactose and displayed large cytoplasmic foci under fluorescent microscopy, two of the dimers enabled the yeast to grow normally in five millimolar galactose, and the AS-GFP became localized to the periphery of the cell. Both dimers were superior when compared to the monomeric compounds.

“Many of the current therapeutic compounds focus on boosting the dopamine output of surviving cells, but this is effective only as long as there are still enough cells to do the job,” said senior author Dr. Jeremy Lee, professor of biochemistry at the University of Saskatchewan. “Our approach aims to protect dopamine-producing cells by preventing alpha-synuclein from misfolding in the first place. Our results suggest these novel bifunctional dimers show promise in preventing the progression of Parkinson’s disease.”

Related Links:
University of Saskatchewan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.